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ABSTRACT: 
Background: IPMNs are cystic pancreatic lesions with variable malignant potential. 
Thrombospondin-2 (THBS2)—an endogenous, anti-angiogenic matrix glycoprotein—may 
modulate tumor progression. We hypothesized that circulating levels of THBS2 could aid in 
preoperative prediction of malignant IPMN. 
Methods: Preoperative serum/plasma samples were procured from patients undergoing surgery. 
Circulating levels of THBS2 were measured (enzyme-linked immunosorbent assay) and 
compared to surgical pathology IPMN dysplastic grade.  
Results: 164 patients underwent THBS2 testing (100 Low/Moderate-IPMN; 64 High-
Grade/Invasive-IPMN). Circulating THBS2 (mean±SD) was greater in High-Grade/Invasive-
IPMN than Low/Moderate-grade IPMN (26.6±12.7ng/mL vs. 20.4±8.2ng/mL; P<0.001). THBS2 
(AUC=0.65) out-performed CA19-9 (n=144; AUC=0.59) in predicting IPMN grade. The 
combination of THBS2, CA19-9, radiographic main-duct involvement, main-duct diameter, age, 
sex, and BMI (AUC 0.83; n=137) provided a good prediction model for IPMN grade. 
Conclusion: Circulating THBS2 is correlated with IPMN dysplasia grade. THBS2 alone did not 
strongly predict IPMN grade but rather strengthened prediction models for High-Grade/Invasive 
IPMN when combined with other clinical/biomarker data. 
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INTRODUCTION: Intraductal papillary mucinous neoplasms (IPMN), one of the few known 
premalignant lesions of the pancreas, may progress through grades of dysplasia to invasive 
cancer.[1] The most widely accepted management strategy for IPMN is outlined by the 
International Consensus Guidelines, which have proven to be limited by poor specificity for 
predicting high-risk lesions.[2, 3] The latest revision in 2016 is the first to introduce a blood 
biomarker, carbohydrate antigen (CA) 19-9 to the algorithm.[4]   
CA19-9 has been shown to predict invasiveness of IPMN,[5] but must be used with 
caution. Benign biliary processes and other gastrointestinal malignancies have been associated 
with increased CA19-9 levels,[6] and approximately 5% of  individuals lack the Lewis blood 
group antigen that allows for an increase in serum CA19-9 levels.[7] Thus, while CA19-9 may 
enhance our ability to risk-stratify patients with IPMN, these pitfalls, together with limitations of 
the International Consensus Guidelines largely based on clinical and radiological features, 
highlight the need for novel, complementary biomarkers. 
Thrombospondin-2 (THBS2) is an extracellular matrix protein that modulates cell 
migration and angiogenesis,[8] two important features involved in tumor progression. Few have 
examined the role of THBS2 in pancreatic disease including pancreatic cancer. A recent study by 
Kim et al. revealed increasing levels of circulating THBS2 with increasing stage of pancreatic 
ductal adenocarcinoma (PDAC). Although 115 patients with IPMN were included in this study, 
they were treated as cases of benign pancreatic disease in data analysis and were not analyzed 
independently.[9] 
As circulating THBS2 has shown promise in predicting progression of PDAC, we 
hypothesized that THBS2—particularly when combined with existing diagnostic modalities 
(radiographic findings, CA19-9)—may also enhance our ability to predict dysplastic grade of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
IPMN preoperatively. With this knowledge, we may begin to build a panel of tumor biomarkers 
to complement our current management algorithm, and better select which patients require 
surgery for high-risk disease (high-grade (HGD)/Invasive-IPMN) while avoiding unnecessary 
surgical morbidity for patients with low-risk lesions (Low/Moderate-IPMN). 
METHODS:  After obtaining informed consent, blood samples were prospectively gathered 
from patients undergoing care for IPMN or pancreatic cancer at Indiana University Health-
University Hospital. Samples were collected at the time of preoperative endoscopic evaluation or 
surgery (May 2003 - February 2017). Blood samples were transported on ice and then processed 
to isolate plasma or serum. Aliquots were stored at -80°C. Samples were thawed on ice and 
tested for circulating levels of thrombospondin-2 (THBS2) using a commercially available 
enzyme-linked immunosorbent assay (ELISA) kit (Cat #DTSP20; R&D; Minneapolis, MN). 
Only first- or second-thaw samples were used; tests were performed on a subset of patients to 
determine that this number of freeze/thaw cycles or the use of plasma versus serum did not affect 
the results. 
Diagnoses for all patients were confirmed by surgical pathology using the World Health 
Organization criteria for dysplastic grade. Clinical data were supplemented through review of the 
electronic medical records. Pancreatitis was a clinical diagnosis and included those with 
characteristic symptoms (epigastric abdominal pain radiating to the back) noted to be pancreatitis 
by the physician, or prior hospitalization for pancreatitis, with or without documented elevation 
in serum pancreatic enzymes. All data were gathered and recorded in compliance with the 
Indiana University Institutional Review Board guidelines. 
Patients were grouped based on grade of dysplasia. Biomarker levels, demographic 
features, and clinical characteristics were compared between groups using Student’s-t test or 
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analysis of variance (ANOVA) for continuous variables and Chi-square test for categorical 
variables. A p-value of <0.05 was considered statistically significant. Receiver operating 
characteristic (ROC) curve analysis was used to determine predictive accuracy of individual 
features and combinations.  
RESULTS:  A total of 164 patients underwent testing for THBS2 (100 Low/Moderate-IPMN, 
38 HGD-IPMN, 26 Invasive-IPMN). Groups based on dysplasia (Low/Moderate, HGD/Invasive) 
were similar in age, sex, race, and clinical history of pancreatitis (p>0.05). Those with 
HGD/Invasive-IPMN had slightly lower BMI (25.9 vs. 27.9; p=0.015), larger main-duct 
diameter (8.6mm vs. 5.3mm; p<0.0001), and more frequent main-duct involvement based on 
pre-operative imaging (78% vs. 36%; p<0.0001).  
 Patients with Low/Moderate-IPMN had significantly lower levels of circulating THBS2 
compared to patients with HGD/Invasive-IPMN (mean ± standard deviation: 20.4 ± 8.2ng/mL 
vs. 26.6 ± 12.7ng/mL; p=0.0007) (Figure Ia). When patients were sub-divided further 
(Low/Moderate-IPMN vs. HGD-IPMN vs. Invasive-IPMN), there was a step-wise increase in 
circulating THBS2 with progressive grade of dysplasia. Patients with Invasive-IPMN had the 
highest level of circulating THBS2 (30.4 ± 12.7ng/mL) compared to those with HGD-IPMN 
(24.1 ± 12.1ng/mL) and Low/Moderate-IPMN (20.4 ± 8.2ng/mL) (p<0.0001) (Figure Ib). On 
individual t-tests, circulating levels of THBS2 were significantly different between Invasive-
IPMN vs. HGD-IPMN (p=0.0495) and Low/Moderate-IPMN (p=0.0006), but not between HDG-
IPMN and Low/Moderate-IPMN (p=0.092). When patients with conventional pancreatic 
adenocarcinoma (PDAC) were included, this trend of increased THBS2 levels and progressive 
dysplasia continued. Those with PDAC (n=30) had greater levels of circulating THBS2 (37.4 ± 
19.1ng/mL) than all other groups, and mean levels varied significantly by dysplastic grade on 
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ANOVA (p<0.0001) (Figure Ic). Individual t-tests showed significant differences in the levels 
of THBS2 between patients with Low/Moderate-IPMN versus PDAC (p<0.0001), as well as 
patients with HGD-IPMN versus PDAC (p=0.0016). There was a similar but non-significant 
difference between those with Invasive-IPMN and PDAC (p=0.104). 
 On ROC curve analysis, THBS2 outperformed the traditionally used blood biomarker, 
CA19-9, in predicting HGD/Invasive-IPMN. Circulating CA19-9 levels did not differ 
significantly between patients with Low/Moderate-IPMN versus HGD/Invasive-IPMN (30.1 ± 
62.1 U/mL vs. 468.2 ± 1,858.3 U/mL; p=0.075), though there was a trend toward increasing 
levels of CA19-9 and increased IPMN grade. THBS2 alone provided an area under the ROC 
curve (AUC) of 0.65 compared to only 0.59 for CA19-9; together, these blood biomarkers 
revealed a predictive accuracy of 0.66. The addition of two clinical features—main-duct 
diameter and radiographic main-duct involvement—to a model including THBS2 and CA19-9 
yielded an AUC of 0.81; this was strengthened with the addition of age, sex, and BMI to the 
model (AUC 0.83). Predictive accuracies of individual components and their combinations are 
outlined in Table I. 
DISCUSSION:  Despite extensive clinical evaluation, predicting which IPMN will progress to 
invasive cancer is difficult. While the International Consensus Guidelines continue to 
improve,[4] they are heavily focused on clinical and radiographic features to guide management. 
In an effort to understand and manage pancreatic cysts at a more individual level, studies focused 
on tumor genetics, molecular profiling, and serum/cyst fluid biomarkers have appropriately 
gained favor. In the present study we examined whether circulating levels of THBS2 could 
predict HGD or Invasive IPMN. We report that THBS2 levels were significantly greater with 
progressive grades of IPMN dysplasia. Moreover, THBS2 out-performed the currently used 
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biomarker, CA19-9, on ROC curve analysis. Our findings suggest that a more practical use of 
THBS2 as a biomarker is in combination with other clinical features, as this more realistically 
approximates clinical decision-making. We showed that together with other factors commonly 
available in routine workup (demographics, radiographic features, CA19-9 level), THBS2 
enhances prediction modeling for IPMN dysplasia. Ultimately, this will aid the clinician in 
deciding which patients with IPMN should continue to be surveilled and which should undergo 
surgical resection. 
 A recent study by Kim et al. revealed that THBS2 levels showed great promise in 
predicting progressive stages of PDAC. THBS2 alone provided an AUC of 0.875 for 
distinguishing between patients with PDAC and healthy controls. With a THBS2 level of 42 
ng/mL as the cutoff point, they reported 52% sensitivity and 99% specificity for detecting 
PDAC. As in our study, they found that THBS2 levels were complementary to other clinical 
features in predicting PDAC: when combined with CA19-9 levels, sensitivity and specificity for 
PDAC reached 87% and 99%, respectively. The ability of THBS2 to distinguish IPMN (n=115) 
from conventional PDAC was also examined, with a reported AUC of 0.784. However, the 
grades of IPMN dysplasia were not considered, and IPMN were not examined as a separate 
entity.[9] As IPMN are pre-malignant lesions of the pancreas, with Invasive-IPMN resembling 
PDAC (arising from pancreatic intraepithelial neoplasia), it follows that a biomarker of PDAC 
such as THBS2 may also predict IPMN progression. However, compared to the study by Kim et 
al., our results for Low/Moderate-IPMN compared to HGD/Invasive-IPMN were more modest. 
This is plausible, as Low/Moderate/HGD-IPMN are all neoplastic, pre-malignant lesions, and 
one would not expect to see such a stark contrast in THBS2 levels amongst these dysplastic 
grades when compared to the extremes of PDAC and healthy controls reported in the prior study.  
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 The exact mechanisms linking circulating THBS2 and pancreatic disease, including 
PDAC and IPMN, are not well understood. Previous studies have suggested a link between 
elevated pancreatic enzymes, pancreatitis or inflammation and progressive grades of IPMN 
dysplasia.[10] Pancreatic stellate cells (PSC) are a type of mesenchymal cell that play a central 
role in the production of extracellular matrix after a pancreatic injury, as in pancreatitis. They 
have also been implicated as an important part of the pancreatic tumor environment.[11, 12] A 
study by Neuschwander-Tetri et al. demonstrated that THBS2 levels increased significantly in a 
mouse model of induced pancreatitis; PSCs were isolated, and found to be a potential source of 
this increase in THBS2.[11] Another study by Farrow et al. examined the role of PSCs in cancer 
invasion rather than pancreatitis or fibrogenesis. In this cell-culture study, PSCs expressing 
greater levels of THBS2 promoted migration of pancreatic cancer cells, whereas PSCs with low 
THBS2 expression attenuated pancreatic cancer cell invasion.[12] While this study by Farrow et 
al. focused on PDAC rather than IPMN, these studies considered together may suggest a 
connection between inflammation, pancreatic stellate cells, THBS2, and progressive dysplasia of 
pancreatic neoplasms, including PDAC and IPMN. Of note, there was no difference in the rate of 
reported pancreatitis between those with Low/Moderate-IPMN and HGD/Invasive-IPMN in our 
study. 
 The present study poses several limitations and opportunities. As a surgical series, this 
cohort does not well represent the entire IPMN population, as most patients with IPMN in the 
current era undergo surveillance rather than surgical resection. It is therefore unclear if our 
findings are generalizable to patients with known IPMN undergoing primary surveillance. 
Longitudinal collection of blood samples from the same patient over time, to observe the trends 
in THBS2 levels on an individual level, may be of benefit if a patient under surveillance 
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undergoes malignant transformation and eventually requires surgery. A steady increase in 
THBS2 levels over time, with eventual HGD/Invasive-IPMN on surgical pathology would 
further support our findings. Though our database overall is prospectively maintained, certain 
clinical features were retrospectively gathered. Finally, while THBS2 did enhance predictive 
capacity for IPMN dysplastic grade, it did not reach the levels of sensitivity and specificity to be 
used as a stand-alone test. Though THBS2 out-performed CA19-9 on predicting HGD/Invasive-
IPMN, it alone was only a moderate predictor of IPMN grade. This observation is not surprising, 
and supports the need for ongoing research to build a panel of complementary biomarkers that 
may predict which IPMN truly require surgery for high-risk biology. To our knowledge, this is 
the first study to date examining the ability of THBS2 to predict dysplastic grade of IPMN. 
Therefore, validation of our results is warranted in larger, prospective, multi-institutional studies.  
CONCLUSION:  Optimal management of IPMN relies on the clinician’s ability to determine 
which lesions are high-risk (i.e. harbor HGD or Invasive disease). We examined the level of 
circulating THBS2 in 164 patients with IPMN, and found that THBS2 level increases with 
progressive grades of IPMN dysplasia. Though THBS2 considered alone was a modest predictor 
of IPMN dysplasia grade, the addition of THBS2 in models utilizing currently employed features 
(CA19-9 level, radiographic findings) enhanced the ability to predict HGD/Invasive IPMN. The 
use of THBS2 may assist in more appropriately recommending surgery for high-risk disease 
while avoiding unnecessary resection of low-risk lesions.  
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Table I. Predictive accuracy of selected biomarkers for IPMN malignancy (High Grade/Invasive 
IPMN vs. Low/Moderate IPMN) 
Prediction Models N AUC 95% CI 
Model 1: THBS2 164 0.65 0.56 – 0.73 
Model 2: CA19-9 144 0.59 0.49 – 0.70 
Model 3: THBS2, CA19-9 144 0.66 0.56 – 0.75 
Model 4: Rad. MD involvement 164 0.71 0.64 – 0.78 
Model 5: MPD diameter 155 0.74 0.66 – 0.82 
Model 6: MPD diameter, Rad. MD involvement 155 0.78 0.71 – 0.85 
Model 7: MPD diameter, Rad. MD involvement, age, sex, BMI 213 0.79 0.73 – 0.85 
Model 8: MPD diameter, Rad. MD involvement, THBS2 189 0.79 0.73 – 0.86 
Model 9: MPD diameter, Rad. MD involvement, CA19-9 189 0.79 0.73 – 0.86 
Model 10: MPD diameter, Rad. MD involvement, THBS2, CA19-9 137 0.81 0.73 – 0.88 
Model 11: MPD diameter, Rad. MD involvement, age, sex, BMI,    
 THBS2 
152 0.82 0.75 – 0.89 
Model 12: MPD diameter, Rad. MD involvement, age, sex, BMI, 
 CA19-9 
189 0.82 0.76 – 0.88 
Model 13: MPD diameter, Rad. MD involvement, age, sex, BMI, 
 THBS2, CA19-9 
137 0.83 0.76 – 0.90 
AUC Area Under the Receiver Operating Characteristic curve; THBS2 Thrombospondin-2; Rad. 
MD involvement Radiographic main-duct involvement; MPD Main pancreatic duct diameter; BMI 
Body mass index 
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FIGURE HEADINGS: 
Figure I 
a. Scatterplot of Circulating Thrombospondin-2 Levels for Low/Moderate-IPMN versus 
HGD/Invasive-IPMN (mean and standard deviation bars shown in red) 
b. Scatterplot of Circulating Thrombospondin-2 Levels for Low/Moderate-IPMN versus HGD-
IPMN versus Invasive-IPMN (mean and standard deviation bars shown in red) 
c. Scatterplot of Circulating Thrombospondin-2 Levels for Low/Moderate-IPMN versus HGD-
IPMN versus Invasive-IPMN versus PDAC (mean and standard deviation bars shown in red) 
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Figure I 
a.  
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HIGHLIGHTS/SUMMARY: 
 
Optimal management of IPMN relies on the clinician’s ability to determine which lesions are 
high-risk (i.e. harbor HGD or Invasive disease). Though THBS2 considered alone was a modest 
predictor of IPMN dysplasia grade, the addition of THBS2 in models utilizing currently 
employed features (CA19-9 level, radiographic findings) enhanced the ability to predict 
HGD/Invasive IPMN. The use of THBS2 may assist in more appropriately recommending 
surgery for high-risk disease while avoiding unnecessary resection of low-risk lesions. 
 
